XML 52 R16.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2015

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Quarter Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2015		2014		2015		2014
Japan	License	$	414	$	118	$	942	$	348
	Milestones		—		—		—		—
	Total license and milestone revenue		414		118		942		348
	Collaboration services revenue*	$	57	$	89	$	157	$	265

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2015		Deferred Revenue at September 30, 2015		Total Consideration Through September 30, 2015
License	$	42,163	$	—	$	42,163
When and if available compounds		14		28		42
Manufacturing--clinical supplies		1,926		36		1,962
Committee services		16		1		17
Total license and collaboration services revenue	$	44,119	$	65	$	44,184

When and if available compounds, manufacturing—clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the collaboration services revenue line item within the condensed consolidated statements of operations.

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Quarter Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2015		2014		2015		2014
Europe	License	$	4,706	$	3,387	$	13,730	$	9,617
	Milestones		—		—		—		—
	Total license and milestone revenue		4,706		3,387		13,730		9,617
	Collaboration services revenue*	$	812	$	801	$	2,065	$	2,242

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2015		Deferred Revenue at September 30, 2015		Total Consideration Through September 30, 2015
License	$	397,369	$	—	$	397,369
When and if available compounds		320		436		756
Manufacturing--clinical supplies		9,318		200		9,518
Development services--in progress		31,838		—		31,838
Committee services		268		7		275
Total license and collaboration services revenue	$	439,113	$	643	$	439,756

When and if available compounds, manufacturing—clinical supplies, development services—in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the collaboration services revenue line item within the condensed consolidated statements of operations.

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Quarter Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2015		2014		2015		2014
U.S. / RoW	License	$	7,925	$	5,521	$	101,758	$	96,209
	Milestones		—		—		15,000		—
	Total license and milestone revenue		7,925		5,521		116,758		96,209
	Collaboration services revenue*		5,614		3,744		22,694		12,769
	China single unit of accounting**	$	—	$	—	$	—	$	—

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2015		Deferred Revenue at September 30, 2015		Total Consideration Through September 30, 2015
License	$	277,132	$	—	$	277,132
Co-development, information sharing & committee services		43,160		41,097		84,257
Manufacturing--clinical supplies		197		91		288
China-single unit of accounting		—		56,805		56,805
Total license and collaboration services revenue	$	320,489	$	97,993	$	418,482

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing—clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.